Efficacy and Safety of a Microsomal Triglyceride Transfer Protein Inhibitor in Homozygous Familial Hypercholesterolemia

Схожие документы

• The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial
  по: Stefanutti, C, et al.
  Опубликовано: (2015)
• Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
  по: Stefanutti, Claudia
  Опубликовано: (2020)
• Correction to: Lomitapide – a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
  по: Stefanutti, Claudia
  Опубликовано: (2020)
• Long term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia
  по: Raper, Anna, et al.
  Опубликовано: (2014)
• Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
  по: Ajufo, Ezim, et al.
  Опубликовано: (2016)